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Abstract
Background:  To describe immune and endocrine responses in severe hymenoptera
hypersensitivity requiring venom immunotherapy (VIT) during in vitro fertilization (IVF).
Case presentation: A 39-year old patient was referred for history of multiple miscarriage and a
history of insect sting allergy. Four years earlier, she began subcutaneous injection of 100 mcg
mixed vespid hymenoptera venom/venom protein every 5–6 weeks. The patient had one livebirth
and three first trimester miscarriages. Allergy treatment was maintained for all pregnancies ending
in miscarriage, although allergy therapy was discontinued for the pregnancy that resulted in
delivery. At our institution ovulation induction incorporated venom immunotherapy (VIT) during
IVF, with a reduced VIT dose when pregnancy was first identified. Serum IgE was monitored with
estradiol during ovulation induction and early pregnancy. Response to controlled ovarian
hyperstimulation was favorable while VIT was continued, with retrieval of 12 oocytes. Serum RAST
(yellow jacket) IgE levels fluctuated in a nonlinear fashion (range 36–54%) during gonadotropin
therapy and declined after hCG administration. A healthy female infant was delivered at 35 weeks
gestation. The patient experienced no untoward effects from any medications during therapy.
Conclusion: Our case confirms the safety of VIT in pregnancy, and demonstrates RAST IgE can
remain <60% during IVF. With proper monitoring, VIT during IVF can be safe and appropriate for
selected patients and does not appear to adversely affect blastocyst implantation, early embryo
development or perinatal outcome. Further studies will be needed to develop VIT guidelines
specifically applicable to IVF.
Introduction
Insect sting allergies affect approximately 3% of the gen-
eral population, and patients with insect sting allergy dur-
ing pregnancy are generally advised to continue venom
immunotherapy (VIT). However, there have been no
descriptions of VIT during infertility therapy despite
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increased utilization of the advanced reproductive tech-
nologies [1]. In this report, we present endocrine and
immunologic parameters observed during a successful in
vitro fertilization cycle where a standard insect sting
allergy protocol was used.
Case report
A 39 year-old Caucasian G4P1031 was referred for evalua-
tion and management of recurrent pregnancy loss. Medi-
cal history was significant for known carrier state for β-
thalassemia. Mild hypothyroidism had been diagnosed in
2002 with immediate initiation of replacement therapy.
The patient was a non-smoker, in good general health and
had no gynecologic complaint. BMI was 21.7 kg/m2. In
1997, she experienced a severe hypotensive anaphylactic
reaction following a yellow jacket sting (Vespula  spp.)
resulting in a full allergy work-up. The patient began sub-
cutaneous injection of 100 mcg mixed vespid hymenop-
tera venom/venom protein (Pharmalgen®; ALK Abello,
Hørsholm, Denmark) every 5–6 weeks, which was well
tolerated.
All four conceptions were established without medical
assistance, involved the same partner, and were achieved
after the hymenoptera hypersensitivity diagnosis. The ini-
tial pregnancy occurred three years before presentation
and resulted in a first trimester spontaneous abortion. No
adjustment was made to the allergy injection regimen dur-
ing that pregnancy. Fetal cardiac activity was initially
present, but was lost at 10 weeks' gestation for unknown
reasons. No curettage was performed.
One year later, a second pregnancy was established but for
this pregnancy hymenoptera venom therapy was discon-
tinued when pregnancy was first recognized (~6 weeks). A
3170 g female infant was delivered vaginally at 40 1/2
weeks' gestation. In 2001 and 2002, the patient estab-
lished two additional pregnancies and hymenoptera ther-
apy was maintained at 5–6 week intervals for both; both
resulted in first trimester spontaneous abortions. For
these miscarriages, dilation and curettage was undertaken
but no karyotype was performed and no cause for the
losses was identified.
At our institution, euthyroid status was verified, the tha-
lassemia carrier state was confirmed, and we identified a
new homozygous A223V mutation at the methyltetrahy-
drofolate reductase (MTHFR) locus. Folic acid intake was
immediately increased to 800 mcg/d, although a baseline
serum homocysteine level was not measured. Factor V Lei-
den, protein S, protein C, and other coagulation tests were
normal, as were karyotypes obtained from both partners.
Anticardiolipin, antiphospholipid and antiovarian anti-
body titres were all negative. However, transvaginal saline
uterine sonography revealed a uniform 5 mm echodense
lesion consistent with an endometrial polyp. Outpatient
hysteroscopic polypectomy was performed without com-
plication. After discussing various infertility therapies and
associated success rates given her age, the patient elected
to undergo IVF.
In March 2003, the patient began programmed ovarian
hyperstimulation using a combined recombinant-
FSH+hMG protocol (300 IU/d Humegon®, Ferring Phar-
maceuticals Inc.; Tarrytown, NY USA and 300 IU/d Gonal-
F®, Serono Labs; Norwell, MA USA). Pre-treatment pitui-
tary downregulation was achieved via 5 u/d leuprolide
acetate and was continued × 3 d after gonadotropin ther-
apy commenced. No alteration was made in the patient's
allergy injection sequence during ovulation induction
(i.e., 100 mcg every 5–6 weeks), and serum yellow jacket
RAST IgE measurements were obtained via commercial
fluoroimmunoassay including positive and negative con-
trols (UniCAP® IgE kit, Pharmacia Diagnostics, Uppsala,
Sweden). While absolute IgE levels remained <0.35 kU/l
throughout therapy, percentage IgE results were variable
and these data are summarized in Figure 1.
On cycle day 10, subcutaneous hCG (10,000 IU) was
given [2] with serum estradiol at 1090 pg/ml. Twelve
oocytes were retrieved and 7 advanced to the 2pn stage fol-
lowing conventional insemination. A four-day course of
methylprednisolone (16 mg/d) was started on the day of
oocyte retrieval. On post-fertilization day three, the ultra-
sound-guided transfer of four embryos was performed.
Immediately following embryo transfer, the patient was
placed on oral aspirin (81 mg/d) and subcutaneous
heparin (5,000 IU b.i.d). Luteal phase support was
administered as daily 50 mg IM progsterone in oil
injections.
Two weeks after embryo transfer, serum hCG was 72 mIU/
ml. On May 5, 2003, transvaginal ultrasound confirmed a
single intrauterine pregnancy with fetal cardiac rate at
126/min. Progesterone was discontinued at the 10th gesta-
tional week. Immunology and perinatology consultants
agreed with reduced dose allergy protocol through the
third trimester, and hymenoptera venom protein extract
(75 mcg) treatment was maintained to 32 weeks gesta-
tion. The patient experienced no untoward reaction or
hypersensitivity to gonadotropins, VIT, or supplementary
progesterone during therapy.
At 32 weeks, obstetrical sonogram suggested reduced
amniotic fluid levels and the patient was given intramus-
cular betamethasone (12 mg/d × 2 days) and placed on
bedrest. At this point allergy injections were discontinued
since the patient was not outdoors and risk for insect sting
was regarded as low. Intravenous oxytocin was started at
35 weeks due to oligohydramnios and resulted in vaginalClinical and Molecular Allergy 2004, 2:11 http://www.clinicalmolecularallergy.com/content/2/1/11
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delivery of a 2495 g female infant. Mother and baby were
discharged home after an uncomplicated two-day post-
partum course. Allergy injections resumed (100 mcg every
5–6 weeks) when breastfeeding was completed three
months later.
Conclusion
Overall, the incidence of allergy to insect stings is ~3% in
adults [3], with allergy to hymenoptera species venom
comprising an important subset of this population.
Whether or not severe insect sting allergy contributes to
poor reproductive outcome has been discussed in earlier
reports [3-5], yet the immunology of pregnancy remains
complex and poorly understood. While connections
between infertility/spontaneous abortion and immune
dysfunction have been explored by others [6,7], the
reported conclusions have been highly variable [8,9]. In
addition, difficulty with immunoassay standardization
has made some findings difficult to reproduce [10].
Although continuation of allergy therapy during preg-
nancy is generally recommended [11], the interaction
between ovulation induction agents and hymenoptera
venom therapy has never been characterized. Our patient
experienced no hypersensitivity or untoward effects dur-
ing allergy therapy and gonadotropin use; both were well
tolerated when administered together. We observed a var-
iable IgE pattern, with a gradually increasing IgE response
progressing with follicular growth during ovulation
induction. Interestingly, a sharply diminished IgE level
Relationships among serum luteinizing hormone (LH-blue), estradiol (E2-black), and yellow jacket RAST %IgE (IgE-red)  observed during in vitro fertilization and concomitant venom immunotherapy Figure 1
Relationships among serum luteinizing hormone (LH-blue), estradiol (E2-black), and yellow jacket RAST %IgE (IgE-red) 
observed during in vitro fertilization and concomitant venom immunotherapy.
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was registered immediately after hCG administration. The
significance of the reduced terminal immunoglobulin
titre is unkown but may reflect an immunomodulatory
attenuation effect of hCG and/or progesterone [12].
Evaluation of this patient with a history of multiple spon-
taneous abortions identified additional factors which
might contribute to a poor reproductive outcome. Specif-
ically, endometrial polyps [13] and homozygous MTHFR
mutation [14] are recognized independent risk factors for
miscarriage. In addition to venom protein, our patient
received other medications which modify immune
response including aspirin [15], heparin [16], progester-
one [17], and human chorionic gonadotropin [12]. Meth-
ylprednisolone [18] was administered at embryo transfer
and betamethasone was given near delivery [19]. While
for our patient VIT was a component of therapy culminat-
ing in a satisfactory reproductive outcome, the result
should be recognized as the sum of all clinical interven-
tions and insufficient data exists to ascribe specific roles
for individual treatments. Levels of IgG4 blocking anti-
body were not quantified in this study, although measure-
ment of this parameter in subsequent studies may offer
additional insight into potential mechanisms of protec-
tion (i.e., reduction of miscarriage risk).
It has been hypothesized that early production of IL-10
associated with VIT may induce T-cell anergy, dampening
T helper type 2 response and resulting in a T helper type 1
dominant cytokine response. As the role of T helper 1 type
immune response in blastocyst implantation becomes
more completely characterized, T helper type 1 function
may prove to be important in early placental dysfunction
or recurrent pregnancy loss [20]. These potential mecha-
nisms notwithstanding, when anatomic and hematologic
abnormalities were corrected and VIT for insect sting
allergy therapy was continued, a healthy livebirth after IVF
was achieved. Our report offers, for the first time, reassur-
ance for women undergoing IVF who also suffer from
severe insect sting allergy requiring VIT. Data derived from
further studies will be helpful as VIT guidelines are devel-
oped specifically for patients undergoing IVF.
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